Gallbladder tissue transfer of pazufloxacin and its clinical efficacy in surgical infection

• Published in: Japanese Journal of Chemotherapy Vol. 43; no. Supplement2; pp. 402 - 407
• Main Authors: Noga, Katsuhiko, Yokoyama, Isao
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1995; 公益社団法人 日本化学療法学会
• Subjects: PZFX; 外科感染症; 胆嚢組織中濃度; 血清中濃度
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.43.Supplement2_402

Basic (transfer into gallbladder tissue) and clinical studies of pazufloxacin (PZFX), a newly developed piribone-carboxylic acid antimicrobialagent for oral use, were performed. The subjects were 6 patients with cholecystolithiasis with normal liver function who were scheduled for cholecystectomy. PZFX was orally administered in the fasting state preoperatively at a dose of 200mg, and 2 hours later, its serum and gallbladder tissue concentrations were measured. Evaluation was possible in 4 patients. The mean serum concentration was 0.20±0.25μg/ml (0.04-0.57μg/ml), and the mean tissue concentration was 0.26±0.22μg/ml (0.11-0.57mg/g). The mean ratio of the tissue concentration to the serum concentration was 2.22±1.27 (1.00-3.75) The efficacy of PZFX in 14 patients with surgical infection was excellent in 2 patients, good in 9, fair in2 and unevaluable in 1. The efficacy rate was 84.6%(11/13). Bacteriologically, six strains (2 strains of Staphylococcus aureus, one strain of Escherichia coli, 2 strains of Peptostreptococcus, and one strain of Bacteroides fragilis) were isolated from five patients, and all strains were eradicated after the treatment. No side effects were observed during medication. The only abnormal finding on clinical tests was an lymphocytosis in one patient. These findings indicate that PZFX is effective in treating surgical infection. As for transfer of PZFX into gallbladder tissue, further study will be needed.